Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Symbiotic-Lung-10
2025-524825-42-00Phase 2Authorised
- Sponsor
- Pfizer
- Start
- Oct 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 18
01
Overview
Phase 2, open-label trial of PF-08634404 in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Pfizer. Planned start Oct 2026; status: authorised.
02
Drugs
PF-08634404
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2025-524825-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524825-42-00.